|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Immediate Versus Delayed Treatment with EGFR Tyrosine Kinase Inhibitors after First-line Therapy in Advanced Non-small-cell Lung Cancer显示文摘Objective: To analyze the outcomes of patients who received TKI immediately after the first-line without progression as maintenance treatment (immediate group) vs. those received delayed treatment upon disease progression as second-line therapy (delayed group). Methods: The study included 159 no-small-cell lung cancer (NSCLC) patients who received gefitinib or erlotinib as maintenance treatment in the immediate group (85 patients) or as second-line therapy in the delayed group (74 patients). The primary end point was progression-free survival (PFS). EGFR mutation status was detected using denaturing high-performance liquid chromatography (DHPLC). Results: PFS was 17.3 and 16.4 months in the immediate and delayed groups, respectively (hazard ratio [HR], 0.99; 95% Confidence Interval [CI]: 0.69-1.42; P=0.947). In a subgroup analysis that included only patients with EGFR mutation, however, PFS was significantly longer in the immediate group than in the delayed group (HR, 0.48; 95% CI: 0.27-0.85; P=0.012). In patients with wild type EGFR, the risk for disease progression was comparable between the two groups (HR, 1.23; 95% CI: 0.61-2.51; P=0.564). No significant difference was demonstrated between the immediate and delayed group in terms of the overall survival (OS) (26.1 months vs. 21.6 months, respectively; HR=0.53; 95% CI: 0.27 to 1.06; P=0.072). There was also no difference in the incidence of adverse events between the two groups. Conclusions: EGFR TKI maintenance improves PFS in patients with EGFR mutation. Prospectively designed clinical studies that compare TKI immediate vs. delayed treatment after first-line chemotherapy upon disease progression are needed. | Zhi-jie Wang Tong-tong An Tony Mok Lu Yang Hua Bai Jun Zhao Jian-chun Duan Mei-na Wu Yu-yan Wang Ping-ping Li Hong Sun Ping Yang Jie Wang | 2011 | Chinese Journal of Cancer Research2011，23，2： | 1 |
| 2 | Endothelial dysfunction in diabetes显示文摘 | An S De Vriese Tony J Verbeuren Johan Van De Voorde | 2000 | Br J Pharmacol2000，130，5： | 1 |
| 3 | Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastie syndrome progenitors显示文摘 | Tony AN Mani M Myka E | 2006 | Blood2006，108，13： | 1 |
| 4 | Resveratrol inhibits genistein induced multi drug resistance protein 2 (MRP2) expression in HepG2 cells显示文摘 | Kim J H Chen C Tony Kong AN | 2011 | Arch Biochem Biophys2011，512，2： | 1 |
| 5 | Anticarcinogenesis by dietary phytochemicals: cytoprotection by NRF2 in normal cells and cytotoxicity by modulation of transcription factors NF-KB and AP-1 in abnormal cancer cells 显示文摘 | Gopalakrishana A Tony Kong AN | 2008 | Food Chem Toxicol2008，46，4： | 1 |
| 6 | Single Mode DR Filters for Wireless Base Stations显示文摘This paper presents state-of-the-art high Q single-mode dielectric resonator (DR) cavity filters for PCS wireless base stations. DR cavity filters shrink the cavity size significantly more than waveguide cavity filters and offer about twice higher Q than coaxial resonators. Thus, they have important applications in wireless base stations operating below 2.5 GHz. Dual-mode and triple-mode DR cavity filters have existed for a while; however, single-mode DR cavity filters are predominant because they are cheaper to manufacture. This paper summarizes the main characteristics of TE01 mode DR cavities, including mode chart and field distribution, and compares cavity Q with waveguide and combline (coaxial) cavities. Dielectric combline and TM010 mode DR cavities are analyzed and compared to TE01 mode DR cavities. General filter design techniques are discussed, and several design examples are given to show how filter technology has developed. | Marco Song George He Tony An | 2011 | ZTE Communications2011，9，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员